Cachet Pharmaceutical Pvt. Ltd, An ALKEM Group, Baddi, Solan 173205, India.
Cachet Pharmaceutical Pvt. Ltd, An ALKEM Group, Baddi, Solan 173205, India.
Colloids Surf B Biointerfaces. 2015 Feb 1;126:553-60. doi: 10.1016/j.colsurfb.2014.11.022. Epub 2014 Nov 22.
The aim of this study was to develop self emulsifying drug delivery systems (SEDDS) of glipizide and to convert it into solid SEDDS (S-SEDDS) using Syloid(®) 244 FP as adsorbent. Solubility study, ternary phase diagram, robustness to dilution, thermodynamic stability study and globule size analysis were adopted to optimize liquid SEDDS. S-SEDDS were evaluated for various studies including in vivo study. The optimized liquid SEDDS formulation consisted of phosphatidylcholine, Tween 80 and Transcutol P as oil, surfactant and cosolvent. In vivo study demonstrated that blood glucose levels were efficiently controlled with S-SEDDS compared with pure drug. The results of this study suggest the potential use of developed S-SEDDS formulation for the delivery of poorly water-soluble drug glipizide.
本研究旨在开发格列吡嗪自乳化药物递送系统(SEDDS),并使用 Syloid(®) 244 FP 作为吸附剂将其转化为固体 SEDDS(S-SEDDS)。采用溶解度研究、三元相图、稀释稳定性、热力学稳定性研究和液滴大小分析来优化液体 SEDDS。对 S-SEDDS 进行了各种研究评价,包括体内研究。优化的液体 SEDDS 配方由磷脂酰胆碱、吐温 80 和 Transcutol P 作为油相、表面活性剂和共溶剂组成。体内研究表明,与纯药物相比,S-SEDDS 能更有效地控制血糖水平。本研究结果表明,所开发的 S-SEDDS 制剂具有递送难溶性药物格列吡嗪的潜力。